查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1702371

全球左心室輔助裝置（LVAD）市場 - 2025-2033

Global Left Ventricular Assist Device (LVAD) Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球左心室輔助裝置 (LVAD) 市場規模達到 13.1 億美元，預計到 2033 年將達到 26.7 億美元，在 2025-2033 年預測期內的複合年成長率為 8.3%。

左心室輔助裝置 (LVAD) 是一種機械泵，當負責向全身泵送含氧血液的左心室過於虛弱而無法自行完成工作時，用於支持患者心臟的功能。 LVAD 通常用於患有嚴重心臟衰竭的患者，特別是那些無法透過藥物或其他療法控制病情的患者。

LVAD 通常被用作等待心臟移植的患者的臨時解決方案，特別是當他們的心臟功能惡化到沒有機械支持就無法等待的程度時。對於不適合進行心臟移植的患者（由於年齡、合併症或其他因素），LVAD 可以作為治療嚴重心臟衰竭的長期或永久解決方案（目標療法）。

市場動態：

駕駛員和約束裝置

LVAD 技術的不斷進步極大地推動了左心室輔助裝置市場的成長。

從脈動流 LVAD 到持續流 LVAD 的轉變徹底改變了 LVAD 技術。與脈動流裝置相比，連續流裝置更可靠，零件更少，且不易發生機械故障。例如，HeartMate 3 LVAD（雅培）是一種持續流動裝置，已顯示出對患者治療效果的顯著改善。臨床試驗發現，與使用舊式脈動流裝置的患者相比，使用 HeartMate 3 的患者存活率更高且併發症更少。

LVAD 的小型化導致了更小、更有效率的設備的開發。這些設備更容易植入，所需的侵入性更小，並且能為患者提供更好的活動能力。生物相容性材料的改善顯著減少了感染和凝血等併發症。現代 LVAD 採用先進的血液接觸材料，最大限度地降低血栓形成（血塊）的風險，從而改善患者的治療效果。技術進步帶來了更好的密封技術和改進的傳動系統設計，降低了感染和設備故障的風險。

手術植入的複雜性阻礙了市場的成長

雖然左心室輔助裝置 (LVAD) 已被證明是挽救末期心臟衰竭患者生命的解決方案，但其手術植入的複雜性仍然是這些裝置更廣泛應用的重大障礙。植入過程涉及高度複雜的手術並帶來多種風險，這使得擴大 LVAD 的使用成為一個挑戰，特別是在資源受限或專業化程度較低的醫療保健環境中。

LVAD 植入是一項高度複雜的手術，需要大量專業知識，因為它涉及將設備連接到心臟和循環系統。由於該手術的侵入性，感染、出血、血栓形成（血塊）和設備故障等併發症的風險很高。

併發症的高風險會增加患者的發病率和住院時間，使得患者和醫療保健提供者在選擇 LVAD 植入時更加謹慎。這反過來又限制了 LVAD 的採用，尤其是對於健康狀況已經很脆弱且患有其他合併症的患者。 LVAD 植入後的恢復過程很長，需要持續監測感染、出血或幫浦故障等併發症。患者還需要遵循嚴格的術後治療方案，包括抗凝血治療，以防止血栓。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第2章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品類型分類的程式碼片段
  • 按應用程式截取的程式碼片段
  • 最終用戶的程式碼片段
  • 按地區分類

第3章：動態

  • 影響因素
    • 驅動程式
      • LVAD 技術的不斷進步
      • 心臟衰竭盛行率不斷上升
    • 限制
      • 手術植入的複雜性
      • 設備拒絕和不相容的風險
    • 機會
      • 小型化和下一代 LVAD
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大行銷品牌的既定領導者
    • 擁有成熟產品的市場領導者
  • 最新進展與突破
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第 5 章：左心室輔助裝置 (LVAD) 市場（依產品類型）

  • 持續流 LVAD
  • 脈動流左心室輔助裝置

第6章：左心室輔助裝置（LVAD）市場（依應用）

  • 移植橋樑（BTT）
  • 目的地療法（DT）
  • 復甦之橋（BTR）

第 7 章：左心室輔助裝置 (LVAD) 市場（依最終用戶）

  • 醫院
  • 心臟專科診所
  • 門診手術中心
  • 其他

第 8 章：左心室輔助裝置 (LVAD) 市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • Abbott
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 併購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT分析
  • CorWave SA
  • Berlin Heart
  • LivaNova, Inc.
  • Evaheart, Inc.
  • BrioHealth Solutions

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: MD2890

The global left ventricular assist device (LVAD) market size reached US$ 1.31 billion in 2024 and is expected to reach US$ 2.67 billion by 2033, growing at a CAGR of 8.3% during the forecast period 2025-2033.

A Left Ventricular Assist Device (LVAD) is a mechanical pump used to support the function of a patient's heart when the left ventricle, responsible for pumping oxygenated blood throughout the body, is too weak to do so on its own. LVADs are typically used in patients with severe heart failure, particularly those whose condition cannot be managed by medication or other therapies.

LVADs are often used as a temporary solution for patients awaiting a heart transplant, especially when their heart function has deteriorated to a point where they cannot wait without mechanical support. For patients who are not candidates for a heart transplant (due to age, comorbidities, or other factors), LVADs can serve as a long-term or permanent solution (destination therapy) to manage severe heart failure.

Market Dynamics: Drivers & Restraints

Rising advancements in LVAD technology are significantly driving the left ventricular assist device market growth.

The shift from pulsatile-flow LVADs to continuous-flow LVADs has been a game-changer in LVAD technology. Continuous-flow devices are more reliable, have fewer parts, and are less prone to mechanical failure compared to pulsatile-flow devices. For instance, the HeartMate 3 LVAD (Abbott), a continuous-flow device, has shown significant improvement in patient outcomes. In clinical trials, it was found that patients with HeartMate 3 experienced better survival rates and fewer complications compared to those with older pulsatile-flow devices.

Miniaturization of LVADs has led to the development of smaller, more efficient devices. These devices are easier to implant, require less invasive procedures, and offer better mobility for patients. Improvements in biocompatible materials have significantly reduced complications like infection and clotting. Modern LVADs use advanced blood-contact materials that minimize the risk of thrombosis (blood clots), leading to better patient outcomes. Technological improvements have led to better sealing technologies and improved driveline designs, reducing the risk of infections and device malfunctions.

Complexity of surgical implantation is hampering the market growth

While left ventricular assist devices (LVADs) have proven to be life-saving solutions for patients with end-stage heart failure, their surgical implantation complexity remains a significant barrier to the broader adoption of these devices. The implantation process involves highly intricate surgeries and poses several risks, making it a challenge to scale the use of LVADs, particularly in resource-constrained or less-specialized healthcare settings.

LVAD implantation is a highly complex surgery that requires significant expertise as it involves connecting the device to both the heart and the circulatory system. Due to the invasive nature of the procedure, there is a high risk of complications such as infection, bleeding, thrombosis (blood clots), and device malfunctions.

The high risk of complications increases patient morbidity and hospitalization time, making both patients and healthcare providers more cautious about opting for LVAD implantation. This, in turn, limits the adoption of LVADs, especially in patients with additional comorbidities who are already in a fragile state of health. The recovery process following LVAD implantation is lengthy and requires constant monitoring for complications like infection, bleeding, or pump malfunction. Patients also need to follow a strict post-operative regimen, including anticoagulation therapy, to prevent blood clots.

Segment Analysis

The global left ventricular assist device (LVAD) market is segmented based on product type, application, end-user, and region.

Product Type:

The continuous flow LVAD segment is expected to dominate the left ventricular assist device market with the highest market share.

The continuous flow left ventricular assist device is the dominant segment within the LVAD market due to its superior performance, improved patient outcomes, and advancements in technology. Unlike traditional pulsatile-flow LVADs, which mimic the heart's natural pumping action, continuous-flow LVADs provide a steady, continuous flow of blood, offering several advantages that contribute to their growing adoption and market dominance.

Continuous flow LVADs offer better clinical outcomes compared to pulsatile flow devices, particularly in terms of survival rates, reduced complication risks, and long-term device performance. For instance, the HeartMate 3 LVAD, a continuous flow device from Abbott, has shown outstanding results in clinical trials. In the MOMENTUM 3 study, the HeartMate 3 demonstrated an 82.8% survival rate at two years, a significant improvement over the pulsatile flow HeartMate II.

Continuous flow LVADs are more compact and efficient than pulsatile devices, offering significant benefits in terms of device size, weight, and reliability. Continuous flow devices typically have a longer operational life and fewer moving parts, which reduces the likelihood of mechanical failure. As a result, patients with continuous flow LVADs often experience more consistent heart function and better quality of life. Continuous flow LVADs have been shown to carry a lower risk of complications such as pump thrombosis, stroke, and infection, which are often associated with pulsatile devices.

Geographical Analysis

North America is expected to hold a significant position in the global left ventricular assist device market with the highest market share

North America, particularly the United States and Canada, is the leading region in the LVAD market due to its strong healthcare infrastructure, high prevalence of heart failure, advanced medical technology, regulatory approvals, and favorable reimbursement policies. The region accounts for the largest market share globally, with significant contributions from key players like Abbott, Medtronic, and others.

The growing number of heart failure (HF) cases in North America is a major factor driving LVAD adoption. For instance, according to the National Institute of Health (NIH), approximately 6.7 million Americans over 20 years of age have HF, and the prevalence is expected to rise to 8.5 million Americans by 2030. The lifetime risk of HF has increased to 24%; approximately 1 in 4 persons will develop HF in their lifetime. The increasing number of patients with end-stage heart failure has led to a higher demand for LVADs as both Bridge-to-Transplant (BTT) and Destination Therapy (DT).

North America is home to leading LVAD manufacturers, which contribute to rapid product innovations and market growth. For instance, Abbott's HeartMate 3, a continuous flow LVAD, has become the gold standard in mechanical circulatory support.

Competitive Landscape

Top companies in the left ventricular assist device (LVAD) market include Abbott, CorWave SA, Berlin Heart, LivaNova, Inc., Evaheart, Inc., and BrioHealth Solutions, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global left ventricular assist device (LVAD) market report delivers a detailed analysis with 50 key tables, more than 48 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in LVAD Technology
      • 3.1.1.2. Increasing Prevalence of Heart Failure
    • 3.1.2. Restraints
      • 3.1.2.1. Complexity of Surgical Implantation
      • 3.1.2.2. Risk of Device Rejection and Incompatibility
    • 3.1.3. Opportunity
      • 3.1.3.1. Miniaturization and Next-Generation LVADs
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with Largest Marketing Brand
    • 4.1.3. Market Leaders with Established Products
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Unmet Needs and Gaps
  • 4.9. Recommended Strategies for Market Entry and Expansion
  • 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.11. Pricing Analysis and Price Dynamics
  • 4.12. Key Opinion Leaders

5. Left Ventricular Assist Device (LVAD) Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Continuous Flow LVAD*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Pulsatile Flow LVAD

6. Left Ventricular Assist Device (LVAD) Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Bridge to Transplant (BTT)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Destination Therapy (DT)
  • 6.4. Bridge to Recovery (BTR)

7. Left Ventricular Assist Device (LVAD) Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Cardiac Clinics
  • 7.4. Ambulatory Surgical Centers
  • 7.5. Others

8. Left Ventricular Assist Device (LVAD) Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. UK
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Abbott*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. CorWave SA
  • 10.3. Berlin Heart
  • 10.4. LivaNova, Inc.
  • 10.5. Evaheart, Inc.
  • 10.6. BrioHealth Solutions

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us